These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2532697)

  • 21. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice.
    Iwata S; Izumi K; Nomoto M
    Pharmacol Biochem Behav; 1992 Aug; 42(4):803-8. PubMed ID: 1513862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotaxic injection of GD1a ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice.
    Date I; Notter MF; Felten SY; Felten DL
    J Neurosci Res; 1991 Apr; 28(4):525-30. PubMed ID: 1678435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
    Schneider JS; Distefano L
    Neuropharmacology; 1995 May; 34(5):489-93. PubMed ID: 7566482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat.
    Meshul CK; Stallbaumer RK; Allen C
    Psychopharmacology (Berl); 1995 Oct; 121(4):461-9. PubMed ID: 8619009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS; Kean A; DiStefano L
    J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
    Date I; Asari S; Nishimoto A; Felten DL
    No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
    Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
    Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GM1 ganglioside treatment promotes recovery of electrically-stimulated [3H]dopamine release in striatal slices from rats lesioned with kainic acid.
    Raiteri M; Bonanno G; Pende M; Versace P
    Neurosci Lett; 1992 Feb; 136(1):127-30. PubMed ID: 1321965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice.
    Kirchhoff J; Mørk A; Brennum LT; Sager TN
    Neuroreport; 2009 Mar; 20(5):482-6. PubMed ID: 19262413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.
    Hadjiconstantinou M; Neff NH
    Eur J Pharmacol; 1990 May; 181(1-2):137-9. PubMed ID: 1974854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat.
    Jaskiw GE; Bongiovanni R
    Psychopharmacology (Berl); 2004 Feb; 172(1):100-7. PubMed ID: 14586541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy.
    Calderon SF; Sanberg PR; Norman AB
    Brain Res; 1988 May; 450(1-2):403-7. PubMed ID: 2969764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
    Schneider JS; DiStefano L
    Neurology; 1994 Apr; 44(4):748-50. PubMed ID: 8164837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ganglioside interactions with the dopaminergic system of rats.
    Tilson HA; Harry GJ; Nanry K; Hudson PM; Hong JS
    J Neurosci Res; 1988; 19(1):88-93. PubMed ID: 3125345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
    Schneider JS; DiStefano L
    Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-1 and D-2 receptor mediation of sensorimotor behavior in rats depleted of dopamine during development.
    Johnson BJ; Bruno JP
    Behav Brain Res; 1992 Mar; 47(1):49-58. PubMed ID: 1533304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GM1 ganglioside protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse.
    Janson AM; Agnati LF; Fuxe K; Cintra A; Sundstrom E; Zini I; Toffano G; Goldstein M
    Acta Physiol Scand; 1988 Apr; 132(4):587-8. PubMed ID: 3265839
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
    Prasad C; Spahn SA; Ikegami H
    Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J; Pietraszek M; Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.